Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Silence Therapeutics (SLN) over the last 6 years, with Q3 2025 value amounting to -$10.9 million.

  • Silence Therapeutics' Free Cash Flow rose 5720.18% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.6 million, marking a year-over-year decrease of 1413.7%. This contributed to the annual value of -$67.9 million for FY2024, which is 1986.97% down from last year.
  • As of Q3 2025, Silence Therapeutics' Free Cash Flow stood at -$10.9 million, which was up 5720.18% from -$21.8 million recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' Free Cash Flow peaked at $37.0 million during Q2 2021, and registered a low of -$27.5 million during Q4 2024.
  • For the 5-year period, Silence Therapeutics' Free Cash Flow averaged around -$11.5 million, with its median value being -$11.0 million (2022).
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 2144647.82% in 2021, then skyrocketed by 6753.95% in 2024.
  • Over the past 5 years, Silence Therapeutics' Free Cash Flow (Quarter) stood at -$5.8 million in 2021, then tumbled by 176.92% to -$16.1 million in 2022, then crashed by 40.46% to -$22.5 million in 2023, then dropped by 22.16% to -$27.5 million in 2024, then soared by 60.41% to -$10.9 million in 2025.
  • Its Free Cash Flow was -$10.9 million in Q3 2025, compared to -$21.8 million in Q2 2025 and -$12.3 million in Q1 2025.